Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.

Horn DB, Shukla AP, Huang H, Twum E, Allen SE, Kis SG

Obesity pillars14 Jul 2026

PMID42577069PMCIDPMC13453602DOI10.1016/j.obpill.2026.100301PepBankPUB-42577069

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In ATTAIN-1 participants aged ≥65 years, orforglipron 5.5 mg reduced weight by 7.9% versus 1.6% with placebo.
In plain wordsIn older ATTAIN-1 participants, orforglipron 5.5 mg reduced weight more than placebo.
Peptide
Orforglipron
Outcome
DecreaseATTAIN-1 weight change, 5.5 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
5.5 mg once daily · oral · 72 weeksAs given in this study (human).
Measurements
Weight change
−7.9%
orforglipron 5.5 mg
Weight change
−1.6%
placebo
95% confidence interval for percent weight change from baseline
−10 to −5.9%
ATTAIN-1, age ≥65 years, orforglipron 5.5 mg, Week 72
95% confidence interval for percent weight change from baseline
−3.2 to 0.1%
ATTAIN-1, age ≥65 years, placebo, Week 72
P value for percent weight change from baseline
< 0.001 p
ATTAIN-1, age ≥65 years, orforglipron 5.5 mg versus placebo, Week 72
Source sentences
Summary
At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was -7.9% (95% CI: -10.0, -5.9), -11.3% (-13.4, -9.3), and -13.0% (-15.7, -10.4) with orforglipron 5.5 mg, 9 mg, and 17.2 mg, respectively, vs. -1.6% (-3.2, 0.1) with placebo (all p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc subgroup analysis evaluated once-daily orforglipron 5.5 mg, 9 mg, or 17.2 mg vs. placebo as an adjunct to healthy diet and physical activity among participants aged ≥65 years.
Summary · context
Efficacy outcomes were analyzed separately for each trial, and safety data were pooled.
Report a problemFND-4257706901
02HumanRandomized controlled trialEfficacy outcome
In ATTAIN-1 participants aged ≥65 years, orforglipron 9 mg reduced weight by 11.3% versus 1.6% with placebo.
In plain wordsIn older ATTAIN-1 participants, orforglipron 9 mg reduced weight more than placebo.
Peptide
Orforglipron
Outcome
DecreaseATTAIN-1 weight change, 9 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
9 mg once daily · oral · 72 weeksAs given in this study (human).
Measurements
Weight change
−11.3%
orforglipron 9 mg
Weight change
−1.6%
placebo
95% confidence interval for percent weight change from baseline
−13.4 to −9.3%
ATTAIN-1, age ≥65 years, orforglipron 9 mg, Week 72
95% confidence interval for percent weight change from baseline
−3.2 to 0.1%
ATTAIN-1, age ≥65 years, placebo, Week 72
P value for percent weight change from baseline
< 0.001 p
ATTAIN-1, age ≥65 years, orforglipron 9 mg versus placebo, Week 72
Source sentences
Summary
At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was -7.9% (95% CI: -10.0, -5.9), -11.3% (-13.4, -9.3), and -13.0% (-15.7, -10.4) with orforglipron 5.5 mg, 9 mg, and 17.2 mg, respectively, vs. -1.6% (-3.2, 0.1) with placebo (all p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc subgroup analysis evaluated once-daily orforglipron 5.5 mg, 9 mg, or 17.2 mg vs. placebo as an adjunct to healthy diet and physical activity among participants aged ≥65 years.
Summary · context
Efficacy outcomes were analyzed separately for each trial, and safety data were pooled.
Report a problemFND-4257706902
03HumanRandomized controlled trialEfficacy outcome
In ATTAIN-1 participants aged ≥65 years, orforglipron 17.2 mg reduced weight by 13.0% versus 1.6% with placebo.
In plain wordsIn older ATTAIN-1 participants, orforglipron 17.2 mg reduced weight more than placebo.
Peptide
Orforglipron
Outcome
DecreaseATTAIN-1 weight change, 17.2 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
17.2 mg once daily · oral · 72 weeksAs given in this study (human).
Measurements
Weight change
−13%
orforglipron 17.2 mg
Weight change
−1.6%
placebo
95% confidence interval for percent weight change from baseline
−15.7 to −10.4%
ATTAIN-1, age ≥65 years, orforglipron 17.2 mg, Week 72
95% confidence interval for percent weight change from baseline
−3.2 to 0.1%
ATTAIN-1, age ≥65 years, placebo, Week 72
P value for percent weight change from baseline
< 0.001 p
ATTAIN-1, age ≥65 years, orforglipron 17.2 mg versus placebo, Week 72
Source sentences
Summary
At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was -7.9% (95% CI: -10.0, -5.9), -11.3% (-13.4, -9.3), and -13.0% (-15.7, -10.4) with orforglipron 5.5 mg, 9 mg, and 17.2 mg, respectively, vs. -1.6% (-3.2, 0.1) with placebo (all p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc subgroup analysis evaluated once-daily orforglipron 5.5 mg, 9 mg, or 17.2 mg vs. placebo as an adjunct to healthy diet and physical activity among participants aged ≥65 years.
Summary · context
Efficacy outcomes were analyzed separately for each trial, and safety data were pooled.
Report a problemFND-4257706903
04HumanRandomized controlled trialEfficacy outcome
In ATTAIN-2 participants aged ≥65 years, orforglipron 5.5 mg reduced weight by 7.5% versus 2.3% with placebo.
In plain wordsIn older ATTAIN-2 participants, orforglipron 5.5 mg reduced weight more than placebo.
Peptide
Orforglipron
Outcome
DecreaseATTAIN-2 weight change, 5.5 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
5.5 mg once daily · oral · 72 weeksAs given in this study (human).
Measurements
Weight change
−7.5%
orforglipron 5.5 mg
Weight change
−2.3%
placebo
95% confidence interval for percent weight change from baseline
−9.1 to −5.9%
ATTAIN-2, age ≥65 years, orforglipron 5.5 mg, Week 72
95% confidence interval for percent weight change from baseline
−3.1 to −1.4%
ATTAIN-2, age ≥65 years, placebo, Week 72
P value for percent weight change from baseline
< 0.001 p
ATTAIN-2, age ≥65 years, orforglipron 5.5 mg versus placebo, Week 72
Source sentences
Summary
which was similar for those in ATTAIN-2 (orforglipron 5.5 mg: -7.5% [-9.1, -5.9]; 9 mg: -8.3% [-9.7, -6.8]; 17.2 mg: -12.2% [-13.9, -10.6]; placebo: -2.3% [-3.1, -1.4]; all p < 0.001).
Summary
At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was -7.9% (95% CI: -10.0, -5.9)
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc subgroup analysis evaluated once-daily orforglipron 5.5 mg, 9 mg, or 17.2 mg vs. placebo as an adjunct to healthy diet and physical activity among participants aged ≥65 years.
Summary · context
Efficacy outcomes were analyzed separately for each trial, and safety data were pooled.
Report a problemFND-4257706904
05HumanRandomized controlled trialEfficacy outcome
In ATTAIN-2 participants aged ≥65 years, orforglipron 9 mg reduced weight by 8.3% versus 2.3% with placebo.
In plain wordsIn older ATTAIN-2 participants, orforglipron 9 mg reduced weight more than placebo.
Peptide
Orforglipron
Outcome
DecreaseATTAIN-2 weight change, 9 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
9 mg once daily · oral · 72 weeksAs given in this study (human).
Measurements
Weight change
−8.3%
orforglipron 9 mg
Weight change
−2.3%
placebo
95% confidence interval for percent weight change from baseline
−9.7 to −6.8%
ATTAIN-2, age ≥65 years, orforglipron 9 mg, Week 72
95% confidence interval for percent weight change from baseline
−3.1 to −1.4%
ATTAIN-2, age ≥65 years, placebo, Week 72
P value for percent weight change from baseline
< 0.001 p
ATTAIN-2, age ≥65 years, orforglipron 9 mg versus placebo, Week 72
Source sentences
Summary
which was similar for those in ATTAIN-2 (orforglipron 5.5 mg: -7.5% [-9.1, -5.9]; 9 mg: -8.3% [-9.7, -6.8]; 17.2 mg: -12.2% [-13.9, -10.6]; placebo: -2.3% [-3.1, -1.4]; all p < 0.001).
Summary
At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was -7.9% (95% CI: -10.0, -5.9)
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc subgroup analysis evaluated once-daily orforglipron 5.5 mg, 9 mg, or 17.2 mg vs. placebo as an adjunct to healthy diet and physical activity among participants aged ≥65 years.
Summary · context
Efficacy outcomes were analyzed separately for each trial, and safety data were pooled.
Report a problemFND-4257706905
06HumanRandomized controlled trialEfficacy outcome
In ATTAIN-2 participants aged ≥65 years, orforglipron 17.2 mg reduced weight by 12.2% versus 2.3% with placebo.
In plain wordsIn older ATTAIN-2 participants, orforglipron 17.2 mg reduced weight more than placebo.
Peptide
Orforglipron
Outcome
DecreaseATTAIN-2 weight change, 17.2 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
17.2 mg once daily · oral · 72 weeksAs given in this study (human).
Measurements
Weight change
−12.2%
orforglipron 17.2 mg
Weight change
−2.3%
placebo
95% confidence interval for percent weight change from baseline
−13.9 to −10.6%
ATTAIN-2, age ≥65 years, orforglipron 17.2 mg, Week 72
95% confidence interval for percent weight change from baseline
−3.1 to −1.4%
ATTAIN-2, age ≥65 years, placebo, Week 72
P value for percent weight change from baseline
< 0.001 p
ATTAIN-2, age ≥65 years, orforglipron 17.2 mg versus placebo, Week 72
Source sentences
Summary
which was similar for those in ATTAIN-2 (orforglipron 5.5 mg: -7.5% [-9.1, -5.9]; 9 mg: -8.3% [-9.7, -6.8]; 17.2 mg: -12.2% [-13.9, -10.6]; placebo: -2.3% [-3.1, -1.4]; all p < 0.001).
Summary
At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was -7.9% (95% CI: -10.0, -5.9)
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc subgroup analysis evaluated once-daily orforglipron 5.5 mg, 9 mg, or 17.2 mg vs. placebo as an adjunct to healthy diet and physical activity among participants aged ≥65 years.
Summary · context
Efficacy outcomes were analyzed separately for each trial, and safety data were pooled.
Report a problemFND-4257706906
07HumanRandomized controlled trialSafety outcome
In older trial participants, gastrointestinal adverse events with orforglipron were the most common events and generally mild to moderate.
In plain wordsIn older participants, gastrointestinal adverse events with orforglipron were most common and generally mild to moderate.
Peptide
Orforglipron
Outcome
Not applicableGastrointestinal adverse events
Study
n = 613
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
Gastrointestinal adverse events with orforglipron were most common and generally mild to moderate in severity.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc subgroup analysis evaluated once-daily orforglipron 5.5 mg, 9 mg, or 17.2 mg vs. placebo as an adjunct to healthy diet and physical activity among participants aged ≥65 years.
Summary · context
Efficacy outcomes were analyzed separately for each trial, and safety data were pooled.
Report a problemFND-4257706908
08HumanRandomized controlled trialOther
In participants younger than 65 years, findings were reported as comparable to those in participants aged 65 years or older.
In plain wordsFindings in participants under 65 were reported as comparable to those in participants aged 65 or older.
Peptide
Orforglipron
Outcome
Direction not reportedFindings in participants younger than 65 years
Study
n: not reported in source
Comparator
Participants ≥65 years
Outcome group
Overall treatment effect · Whole body
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
Comparable findings were observed in participants <65 years of age.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc subgroup analysis evaluated once-daily orforglipron 5.5 mg, 9 mg, or 17.2 mg vs. placebo as an adjunct to healthy diet and physical activity among participants aged ≥65 years.
Summary · context
Efficacy outcomes were analyzed separately for each trial, and safety data were pooled.
Report a problemFND-4257706907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 3Results postedNCT05869903

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Eli Lilly and Companyn = 3,1275 Jun 2023 to est. Oct 2027

Obesity · Overweight · Overweight or Obesity

Trial page ClinicalTrials.govUpdated 14 Aug 2026

CompletedPhase 3Results postedNCT05872620

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Eli Lilly and Companyn = 1,6135 Jun 2023 to 8 Aug 2025

Obesity · Overweight · Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 4 Sept 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.